382MO Updated results from the phase I/II study of OP-1250, an oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) in patients (pts) with advanced or metastatic ER-positive, HER2-negative breast cancer
Nancy U. Lin, Virginia F. Borges, Manish R. Patel, Meena Okera, Jane Meisel, Robert Wesolowski, Timothy Pluard, Kathy D. Miller, Nicole McCarthy, Alison Conlin, Reshma Mahtani, Dhanusha Sabanathan, Kelly McCann, Erin Roesch, G. Mathauda-Sahota, Joerg H. Schroeder, Erika Hamilton
Topics & Concepts
MedicineNeutropeniaMetastatic breast cancerFulvestrantNauseaInternal medicineVomitingCommon Terminology Criteria for Adverse EventsAdverse effectChemotherapyOncologyFebrile neutropeniaPhases of clinical researchResponse Evaluation Criteria in Solid TumorsBreast cancerGastroenterologyCancerEstrogen receptorAdvanced Breast Cancer TherapiesCancer Treatment and PharmacologyHER2/EGFR in Cancer Research